Dermira, Inc.

If you purchased Dermira, Inc. securities and would like to join the action, please click "Join This Action" below.

DERMIRA MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE SALE OF DERMIRA, INC. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – DERM

January 10, 2020.

New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Dermira, Inc. (NASDAQ: DERM) to Eli Lilly and Company (“Eli Lilly”) for $18.75 per share is fair to Dermira shareholders. On behalf of Dermira shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

The Dermira merger investigation concerns whether Dermira and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to: (1) obtain the best possible price for Dermira shareholders; (2) determine whether Eli Lilly is underpaying for Dermira; and (3) disclose all material information necessary for Dermira shareholders to adequately assess and value the merger consideration.

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Certification

Scroll to Top